Bredesen, Dale E., M.D.
  • Visiting Professor of Neurology

  • Director of Neurodegenerative Disease Research, David Geffen School of Medicine at UCLA

Bredesen, Dale E., M.D.


Mary S. Easton Center for Alzheimer's Disease Research at UCLA
710 Westwood Plaza, Room C-224
Los Angeles, CA 90095-1769
Tel: (310) 794-3665
Fax: (310) 794-3148
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Neurology, Alzheimer's Disease, Dementia, and Memory Disorders.


Education, Training and Appointments

  • B.S., Biology and Literature, California Institute of Technology, Pasadena, CA, 1974.
  • M.D., Duke University Medical Center, Durham, NC, 1977.
  • Resident, Medicine, Duke University Medical Center, Durham, NC, 1978-1980.
  • Resident, Neurology, Chief Resident, UCSF, San Francisco, CA, 1980-1983.
  • Clinical Instructor, Neurology, UCSF, San Francisco, CA, 1983-1987.
  • Hughes Associate, Laboratory of Dr. LY Jan (Drosophila Neurogenetics) Howard Hughes Medical Institute, San Francisco, CA, 1985-1986.
  • NIH Postdoctoral Fellow, Laboratory of Dr. SB Prusiner (Neurodegenerative Disease) University of California, San Francisco, San Francisco, CA, 1986-1989.
  • Assistant Adjunct Professor, UCSF, Department of Neurology, San Francisco, CA 1987-1989.
  • Assistant Professor, UCLA, Department of Neurology, Los Angeles, CA, 1989-1994.
  • Associate Professor, UCLA, Department of Neurology, Los Angeles, CA, 1994-1995.
  • Elizabeth R. and Thomas E. Plott Chair, UCLA, Center on Aging, Los Angeles, CA 1993-1995.
  • Professor and Director, Program on Aging, The Burnham Institute, La Jolla, CA, 1994-1999.
  • Associate Adjunct Professor, UCLA, Department of Neurology, Los Angeles, CA, 1995-1997.
  • Associate Adjunct Professor, Neuroscience Department, UCSD, San Diego, CA, 1996-1998.
  • Adjunct Professor, Neuroscience Department, UCSD, San Diego, CA, 1998-2000.
  • Adjunct Professor, The Burnham Institute, La Jolla, CA, 1999-2005.
  • President and CEO, Buck Institute for Age Research, Novato, CA, 1999-2005.
  • President and CEO, Buck Institute for Age Research, Novato, CA, 1999-2005.
  • Adjunct Professor, UCSF, San Francisco, CA, 1999-present.
  • Scientific Director and CEO, Buck Institute for Age Research, Novato, CA, 2005-2006.
  • Director and CEO, Buck Institute for Age Research, Novato, CA, 2006-2008.
  • Professor and Founding President/CEO, Buck Institute for Age Research, Novato, CA, 2008-present.
  • Honorary Professor, Dominican University, San Rafael, CA, 2008-present.
  • Director, Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Los Angeles, CA, 2013-2015.


Activities and Awards

1970, 1993-1997 Athletic Letters, Caltech (Football, Track)
1970-1974 Alfred P. Sloan Scholar, Caltech
1971 Research Assistant, Caltech (Dr. H. Gray, Inorg. Chemistry)
1972 Research Assistant, MIT (Dr. M. Wrighton, Inorg. Chemistry)
1972 Member, Board of Control, Caltech
1973 NSF Summer Fellow, Caltech (Dr. R. Sperry, Psychobiology)
1974 McKinney Prize for Humanities, Caltech
1974 Graduation with Honor, Caltech
1975-1977 Mary Duke Biddle Scholar, Duke
1977 Brody Scholar in the History of Neurosciences, Duke
1977 Trent Prize in the History of Medicine, Duke
1982 Chief Resident, Neurology, UCSF
1983 Scholarship Recipient, Cold Spring Harbor Neurobiology Seminars
1983 Sandoz Award for Outstanding Neurology Resident, UCSF
1984 Outstanding Faculty Teacher Award, UCSF
1992 Honorable Mention, UCLA Neurology Residents' Teaching Award
1992 Cotzias Award, American Parkinson Disease Foundation
1993-1995 Elizabeth R. and Thomas E. Plott Chair in Gerontology, UCLA
1996 Child Neurology Society Lectureship
1996 Lou and Eleanor Gehrig Lectureship, Columbia University (given for the most outstanding work on amyotrophic lateral sclerosis within the previous year)
1997 United Way Combined Health Agencies Health Hero (annual award for outstanding medical research in San Diego)
2000 Arthur Cherkin Award for Research in Neurodegenerative Disease, UCLA
2005 Gilman-Barbour Distinguished Lecturer, University of Michigan
2010 Editorial Board Member, JBC
2011 Associate Editor, J Alzheimer's Disease
2013 Turken International Lecturer, Neurology Grand Rounds at UCLA
2014 Steven DeArmond Lecture, American Academy of Neuropathologists, Portland, OR


Publications (selected peer-reviewed publications)

  • Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R and Bredesen DE. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta- peptide of APP. Free Radic Biol Med 2010;48:136-144. PMID: 19854267; PMCID: PMC2818480
  • Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E and Mucke L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci 2010;30:372-381. PMID: 20053918; PMCID: PMC3064502
  • Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D Richardson A, Strong R and Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010;5:e9979. PMID: 20376313; PMCID: PMC2848616
  • Zhang J, Gorostiza OF, Tang H, Bredesen DE and Galvan V. Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience. Behav Brain Res 2010;206:202-207. PMID: 19751769; PMCID: PMC2783897
  • Sperandio S., Poksay, KS, Schilling B, Crippen D, Gibson BW, Bredesen DE. Identification of new modulators and protein alterations in non-apoptotic programmed cell death. J Cell Biochem 2010 Dec 15;111(6):1401-1412. doi 10.1002/jcb.22870. PMID: 20830744
  • Bredesen DE, John V, Galvan V. Importance of the caspase cleavage site in amyloid-ß protein precursor. J Alzheimers Disease 2010;22(1):57-63. PMID: 20847422; PMCID: PMC3968071
  • Descamps, O, Zhang, Q, John V, Bredesen DE. Induction of the C-Terminal Proteolytic Cleavage of AßPP by Statins. J Alzheimers Dis 2011;25(1):51-57. doi: 10.3233/JAD-2011-101857. PMID: 21422530
  • Mehlen P and Bredesen DE. Dependence receptors: from basic research to drug development. Sci Sign 2011 Jan 25;4(157):mr2.
  • Poksay, KS, Madden DR, Peter AK, Niazi, K, Banwait, S, Crippen D, Bredese DE, Rao RV. Valosin-containing protein gene mutations: cellular phenotypes relevant to neurodegeneration J Mol Neurosci 2011 Jun:44(2):91-102. PMC: PMC3084943
  • Orcholski, ME, Zhang, Q, Bredesen DE. Signaling via amyloid precursor-like proteins APLP1 and APLP2. J Alzheimers Dis 2011:23(4):689-699. PMID: 21178287
  • Robinson RA, Lange MB, Sultana R, Galvan V, Fombonne J, Gorostiza O, Zhang J, Warrier G, Cai J, Pierce WM, Bredesen DE, Butterfield DA. Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-beta peptide of amyloid precursor protein(Xi). Neuroscience 2011;177:207-222. PMID: 21223993; PMCID: PMC3058851
  • Poksay KS, Banwait S, Crippen D, Mao X, Bredesen DE, Rao RV. The Small Chaperone Protein p23 and Its Cleaved Product p19 in Cellular Stress. J Mol Neurosci 2011;9574-9577. PMID: 21691801; PMCID: PMC3246043
  • Zhang J, Rao RV, Spilman P, Mangada J, Xie L, Vitelli C, Gorostiza OF, Madden DT, Zeng X, Jin K, Hart MJ, Bredesen DE, Galvan V. Endogenously EGFP-Labeled Mouse Embryonic Stem Cells. Aging Dis 2011;2:18-29. PMID: 21874159; PMCID: PMC3160738
  • Madden DT, Davila-Kruger D, Melov S, Bredesen DE. Human Embryonic Stem Cells Express Elevated Levels of Multiple Pro-Apoptotic BCL-2 Family Members. PLoS One 2011;6, e28530, 10.1371/journal.pone.0028530 PONE-D-11-19250. PMID: 22174832; PMCID: PMC3235131
  • Libeu CP, Poksay K., John V, Bredesen DE. Structural and Functional Alterations in Amyloid-B Precursor Protein Induced by Amyloid-B Peptides, J Alzheimers Dis 2011;25:547-566. PMID: 21471643; PMCID: PMC4001850
  • Rao R, Patent A, Zhang Q, Flores S, Bredesen DE. Cellular effects of APOE4: Implications for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2011;7:S569.
  • Libeu CP, Descamps O, Zhang J, John V, Bredesen DE. Altering APP proteolysis: increasing sAPPalpha by targeting dimerization of the APP ectodomain. PLoS One. 2012;7(6):e40027. doi: 10.1371/journal.pone.0040027. PMID: 22768208; PMCID: PMC3386930
  • Choi SW, GA, Ng R, Flynn JM, Melov S, Danielson SR, Gibson BW, Nicholls DG, Bredesen DE, Brand MD. No consistent bioenergetic defects in presynaptic nerve terminals isolated from mouse models of Alzheimer's disease. Journal of Neuroscience 2012;32(47):16775-16784. doi: 10.1523/JNEUROSCI.2414-12.2012. PMID: 3175831; PMCID: PMC3736741
  • Rao R, Descamps O, John V, Bredesen DE. Ayurvedic medicinal plants for Alzheimer's disease: a review. Alzheimers Res Ther 2012 Jun 29;4(3):22. doi: 10.1186/alzrt125. PMID: 22747839; PMCID: PMC3506936
  • Rodríguez Plaza JG, Villalón Rojas A, Herrera S, Garza-Ramos G, Torres Larios A, Amero C, Zarraga Granados G, Gutiérrez Aguilar M, Lara Ortiz MT, Polanco Gonzalez C, Uribe Carvajal S, Coria R, Peña Díaz A, Bredesen DE, Castro-Obregon S, Del Rio G. Correction: Moonlighting peptides with emerging function. PLoS One 2013;8(10). doi: 10.1371/annotation/fc687f18-ce8e-4704-87a5-d6807953204e. eCollection 2013. PMID: 24194802; PMCID: PMC3806584
  • Sultana R, Robinson RA, Lange MB, Fiorini A, Galvan V, Fombonne J, Baker A, Gorostiza O, Zhang J, Cai J, Pierce WM, Bredesen DE, Butterfield DA. Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis? Antioxid Redox Signal 2012;17(11):1507-1514. PMID: 22500616; PMCID: PMC3448937
  • Poksay KS, Banwait S, Crippen D, Mao X, Bredesen DE, Rao RV. The small chaperone protein p23 and its cleaved product p19 in cellular stress. J Mol Neurosci 2012;46(2): 303-314. doi: 10.1007/s12031-011-9574-7. PMID: 21691801; PMCID: PMC3246043
  • Bredesen DE, John V. Next generation therapeutics for Alzheimer's disease. EMBO Mol Med 2013;5(6):795-798. doi: 10.1002/emmm.201202307. PMID: 23703924; PMCID: PMC3779441
  • Descamps O, Spilman P, Zhang Q, Libeu CP, Poksay K, Gorostiza O, Campagna J, Jagodzinska B, Bredesen DE, John V. AbetaPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer's Disease. J Alzheimers Dis 2013;37(2):343-355. doi: 10.3233/JAD-130578. PMID: 23948888; PMCID: PMC3971881
  • Zhang J, Spilman P, Chen S, Gorostiza O, Matalis A, Niazi K, Bredesen DE, Rao RV. The small co-chaperone p23 overexpressing transgenic mouse. J Neurosci Methods 2013;202(2):190-194. doi: 10.1016/j.jneumeth.2012.09.022. PMID: 23022695; PMCID: PMC3562756
  • Theendakara V, Patent A, Peters-Libeu C, Philpot B, Flores S, Descamps O, Poksay K, Zhang Q, Cailing G, Hart M, John V, Rao R, Bredesen D. Neuroprotective sirtuin ratio reversed by ApoE4. PNAS 2013;110(45):18303-18308. doi: 10.1073/pnas.1314145110. PMID: 24145446; PMCID: PMC3831497
  • Spilman P, Descamps O, Gorostiza O, Peters-Libeu C, Poksay K, Matalis A, Patent A, Rao R, John V, Bredesen D. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. Brain Research 2014;1551:25-44. Issue Cover. doi:10.1016/j.brainres.2013.12.029. PMID: 24389031; PMCID: PMC4001856 [Available on 2015/3/10]
  • Zhang Q, Descamps O, Hart MJ, Poksay K, Spilman P, Kane D, Gorostiza O, John V, Bredesen DE. Paradoxical Effect of TrkA Inhibition in Alzheimer's Disease Models. J Alzheimers Dis 2014;40(3):605-617. PMID: 24531152; PMCID: PMC4091737
  • Galluzzi L, Kroemer G, Bredesen DE, et. al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015;22(1):58-73. PMID: 25236395; PMCID: PMC4262782
  • Bredesen DE. Reversal of cognitive decline: A novel therapeutic program. Aging 2014;6(9):707-717. PMID: 25324467; PMCID: PMC4221920
  • Zhang Q, Du G, John V, Kapahi P, Bredesen DE. Alzheimer's Model Develops Early ADHD Syndrome. Journal of Alzheimer's Disease, 2014 May. (Submitted)


  • Bredesen DE. (2010) BACE, APP Processing, and Signal Transduction in Alzheimer's Disease. John, V. (ed.), BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease. John Wiley & Sons, Inc., Hoboken, NJ, pp. 1-14.
  • Bredesen DE. Role of Programmed Cell Death in Neurodegenerative Disease. Reed, J.C. and Green, D. (eds.), Apoptosis: Physiology and Pathology of Cell Death. Cambridge University Press, New York.
  • Bredesen DE. Prionic Loops, Anti-Prions, and Dependence Receptors in Neurodegeneration, Prusiner Beitrag 2013.
  • Jagust W, Bredesen DE, Campisi JC, Lithgow G, Vijg J. Molecular and Cellular Biology of Aging (2013) in press.